This is a StreetInsider.com Premium Only Page

ADC Therapeutics SA (ADCT) – StreetInsider.com Reports

Apr 4, 2024 07:00 AM ADC Therapeutics SA (ADCT) Announces Updates on LOTIS-7 Trial of ZYNLONTA

Mar 28, 2024 06:21 AM Guggenheim Starts ADC Therapeutics (ADCT) at Buy

Mar 13, 2024 04:02 PM ADC Therapeutics (ADCT) PT Lowered to $13 at Jefferies

Mar 13, 2024 07:22 AM ADC Therapeutics SA (ADCT) Misses Q4 EPS by 51c

Feb 26, 2024 07:15 AM ADC Therapeutics (ADCT) PT Raised to $8 at RBC Capital

Feb 20, 2024 06:41 AM ADC Therapeutics (ADCT) PT Raised to $9 at H.C. Wainwright

Jan 19, 2024 04:41 PM ADC Therapeutics SA (ADCT) Enters Amendment to Credit Agreement

Jan 4, 2024 07:16 AM ADC Therapeutics SA (ADCT) Regains Compliance with NYSE Continued Listing Standards

Jan 4, 2024 07:02 AM ADC Therapeutics SA (ADCT) Provides Business Updates

Dec 12, 2023 05:22 AM ADC Therapeutics SA (ADCT) Reports Initial Results from Phase 2 Clinical Trial Evaluating ZYNLONTA in Combination with Rituximab

Nov 20, 2023 06:33 AM ADC Therapeutics (ADCT) PT Lowered to $3 at H.C. Wainwright

Nov 9, 2023 05:29 AM TD Cowen Downgrades ADC Therapeutics (ADCT) to Market Perform

Nov 8, 2023 06:55 AM ADC Therapeutics (ADCT) PT Lowered to $6 at RBC Capital

Nov 7, 2023 07:17 AM ADC Therapeutics SA (ADCT) Tops Q3 EPS by 23c

Nov 7, 2023 07:15 AM ADC Therapeutics SA (ADCT) Receives NYSE Non-compliance Notice

Oct 17, 2023 09:45 AM ADC Therapeutics (ADCT) PT Lowered to $1 at BofA Securities

Sep 14, 2023 09:59 AM ADC Therapeutics (ADCT) PT Lowered to $6 at CapitalOne

Sep 12, 2023 06:16 AM ADC Therapeutics (ADCT) PT Lowered to $8 at RBC Capital

Aug 31, 2023 05:53 AM ADC Therapeutics SA (ADCT) Announces Updates on ZYNLONTA LOTIS Clinical Trial Programs

Aug 10, 2023 05:07 AM JPMorgan Upgrades ADC Therapeutics (ADCT) to Neutral, 'fully valued'

Aug 9, 2023 06:19 AM ADC Therapeutics (ADCT) PT Lowered to $9 at RBC Capital

Aug 8, 2023 07:29 AM ADC Therapeutics SA (ADCT) Tops Q2 EPS by 12c

Jul 24, 2023 07:22 AM Overland ADCT BioPharma (ADCT) Announces NMPA Accepts BLA and Grants Priority Review for ZYNLONTA

Jul 20, 2023 04:06 PM ADC Therapeutics SA (ADCT) to Discontinue the Phase 2 LOTIS-9 Clinical Trial of ZYNLONTA and Rituximab in Unfit or Frail Previously Untreated DLBCL Patients

Jul 12, 2023 08:10 AM ADC Therapeutics (ADCT) PT Lowered to $2 at Morgan Stanley

Jul 11, 2023 07:01 AM ADC Therapeutics SA (ADCT) Announces Voluntary Pause of Enrollment in Phase 2 LOTIS-9 Clinical Trial of ZYNLONTA and Rituximab in Unfit or Frail Previously Untreated DLBCL Patients

Jun 21, 2023 06:36 AM ADC Therapeutics (ADCT) PT Lowered to $12 at H.C. Wainwright

Jun 15, 2023 07:15 AM ADC Therapeutics SA (ADCT) Announces Board Changes

Jun 9, 2023 07:15 AM ADC Therapeutics (ADCT) Announces Updated LOTIS-2 Results Demonstrating Durable, Long-Term Responses of ZYNLONTA in R/R DLBCL

May 10, 2023 06:21 AM ADC Therapeutics (ADCT) PT Lowered to $10 at RBC Capital

May 9, 2023 07:12 AM ADC Therapeutics SA (ADCT) Misses Q1 EPS by 57c

Apr 24, 2023 06:06 AM BofA Securities Downgrades ADC Therapeutics (ADCT) to Underperform

Feb 28, 2023 07:13 AM ADC Therapeutics SA (ADCT) Tops Q4 EPS by 38c

Feb 2, 2023 07:15 AM ADC Therapeutics SA (ADCT) Prices 12M Share Secondary Offering at $5/sh

Jan 5, 2023 04:23 AM ADC Therapeutics SA (ADCT) Enters Development and License Option Agreement with IntoCell

Jan 4, 2023 06:49 AM ADC Therapeutics (ADCT) PT Lowered to $20 at H.C. Wainwright

Jan 3, 2023 04:31 PM ADC Therapeutics SA (ADCT) Appoints Mohamed Zaki as Chief Medical Officer

Dec 21, 2022 05:56 AM ADC Therapeutics (ADCT) and Sobi Granted EU Approval of ZYNLONTA

Dec 20, 2022 12:48 PM ADC Therapeutics SA (ADCT) granted European Commission approval of Zynlonta

Dec 19, 2022 07:17 AM ADC Therapeutics SA (ADCT) Appoints Jose Carmona as CFO

Dec 6, 2022 07:37 AM CapitalOne Starts ADC Therapeutics (ADCT) at Overweight

Nov 28, 2022 09:47 AM Biocytogen Enters into Antibody Agreement with ADC Therapeutics (ADCT)

Nov 9, 2022 06:27 AM ADC Therapeutics (ADCT) PT Lowered to $20 at RBC Capital

Nov 8, 2022 04:43 PM BofA Securities Downgrades ADC Therapeutics (ADCT) to Neutral

Nov 8, 2022 07:05 AM ADC Therapeutics SA (ADCT) Misses Q3 EPS by 30c

Nov 2, 2022 04:07 PM IGM Biosciences Inc. (IGMS) and ADC Therapeutics (ADCT) Announce Clinical Collaboration over Imvotamab (IGM-2323)

Nov 1, 2022 07:15 AM ADC Therapeutics SA (ADCT) Appoints Kristen Harrington-Smith as Chief Commercial Officer

Sep 21, 2022 06:06 AM JPMorgan Starts ADC Therapeutics (ADCT) at Overweight

Sep 19, 2022 06:47 AM ADC Therapeutics (ADCT) PT Raised to $21 at H.C. Wainwright

Sep 16, 2022 07:16 AM ADC Therapeutics SA (ADCT) and Sobi Announce ZYNLONTA Receives Positive CHMP Opinion in Europe for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma